Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 1, 2012, Pages 29-36

  Dorn, Christoph ^a   Heilmann, Jörg ^b   Hellerbrand, Claus ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Acute liver injury; Carbon tetrachloride; Fibrosis; Inflammation; Xanthohumol

Indexed keywords

ANTIINFLAMMATORY AGENT; CARBON TETRACHLORIDE; FLAVONOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROPIOPHENONE DERIVATIVE; XANTHOHUMOL;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL LIVER CIRRHOSIS; FATTY LIVER; FEMALE; GENE EXPRESSION; METABOLISM; MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARBON TETRACHLORIDE; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; FLAVONOIDS; GENE EXPRESSION; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NF-KAPPA B; PROPIOPHENONES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84856722609     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Zanoli P, Zavatti M. Pharmacognostic and pharmacological profile of Humulus lupulus L. J Ethnopharmacol 2008; 116: 383-396.
2. Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry 2004; 65: 1317-1330.
3. Albini A, Dell'Eva R, Vene R, Ferrari N, Buhler DR, Noonan DM and Fassina G. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-κB and Akt as targets. FASEB J 2006; 20: 527-529.
4. Dell'Eva R, Ambrosini C, Vannini N, Piaggio G, Albini A and Ferrari N. AKT/NF-κB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer 2007; 110: 2007-2011.
5. Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S and Aggarwal BB. Modification of the cysteine residues in IκBα kinase and NF-κB (p65) by xanthohumol leads to suppression of NF-κB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood 2009; 113: 2003-2013.
6. Dorn C, Kraus B, Motyl M, Weiss TS, Gehrig M, Scholmerich J, Heilmann J and Hellerbrand C. Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Mol Nutr Food Res 2010; 54: S205-213.
7. Cobbold JF, Anstee QM and Taylor-Robinson SD. The importance of fatty liver disease in clinical practice. Proc Nutr Soc 2010; 69: 518-527.
8. Clark JM, Brancati FL and Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657.
9. Vernon G, Baranova A and Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
10. Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M and Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 2011; 458: 511-523.
11. Gines P, Cardenas A, Arroyo V and Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654.
12. Minguez B, Tovar V, Chiang D, Villanueva A and Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009; 25: 186-194.
13. Villanueva A, Newell P, Chiang DY, Friedman SL and Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76.
14. Cutroneo KR. How is Type I procollagen synthesis regulated at the gene level during tissue fibrosis. J Cell Biochem 2003; 90: 1-5.
15. Lang A, Brenner DA. Gene regulation in hepatic stellate cell. Ital J Gastroenterol Hepatol 1999; 31: 173-179.
16. Brenner DA, Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E, Yamauchi M, Gillan A and Rippe RA. New aspects of hepatic fibrosis. J Hepatol 2000; 32: 32-38.
17. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 2007; 22: S73-78.
18. Maher JJ, Bissell DM. Cell-matrix interactions in liver. Semin Cell Biol 1993; 4: 189-201.
19. Hautekeete ML, Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch 1997; 430: 195-207.
20. Lee KS, Buck M, Houglum K and Chojkier M. Activation of hepatic stellate cells by TGF α and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995; 96: 2461-2468.
21. Lang A, Schoonhoven R, Tuvia S, Brenner DA and Rippe RA. Nuclear factor κB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J Hepatol 2000; 33: 49-58.
22. Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB and Brenner DA. Inhibition of NFκB in activated rat hepatic stellate cells by proteasome inhibitors and an IκB super-repressor. Hepatology 1998; 27: 1285-1295.
23. Grunhage F, Fischer HP, Sauerbruch T and Reichel C. Drug- and toxin-induced hepatotoxicity. Z Gastroenterol 2003; 41: 565-578.
24. Zimmerman HJ, Lewis JH. Chemical- and toxininduced hepatotoxicity. Gastroenterol Clin North Am 1995; 24: 1027-1045.
25. Mehendale HM, Roth RA, Gandolfi AJ, Klaunig JE, Lemasters JJ and Curtis LR. Novel mechanisms in chemically induced hepatotoxicity. FASEB J 1994; 8: 1285-1295.
26. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA and Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004; 101: 4477-4482.
27. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539-548.
28. Gabele E, Muhlbauer M, Dorn C, Weiss TS, Froh M, Schnabl B, Wiest R, Scholmerich J, Obermeier F and Hellerbrand C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun 2008; 376: 271-276.
29. Hellerbrand C, Muhlbauer M, Wallner S, Schuierer M, Behrmann I, Bataille F, Weiss T, Scholmerich J and Bosserhoff AK. Promoterhypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis 2006; 27: 64-72.
30. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Scholmerich J and Hellerbrand C. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCVrelated liver disease. Gastroenterology 2003; 125: 1085-1093.
31. Dorn C, Weiss TS, Heilmann J and Hellerbrand C. Xanthohumol, a prenylated chalcone derived from hops, inhibits proliferation, migration and interleukin-8 expression of hepatocellular carcinoma cells. Int J Oncol 2010; 36: 435-441.
32. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99.
33. Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009; 120: 61-368.
34. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, Clark N and Murphy G. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996; 24: 176-184.
35. Avula B, Ganzera M, Warnick JE, Feltenstein MW, Sufka KJ and Khan IA. High-performance liquid chromatographic determination of xanthohumol in rat plasma, urine, and fecal samples. J Chromatogr Sci 2004; 42: 378-382.
36. Bolca S, Li J, Nikolic D, Roche N, Blondeel P, Possemiers S, De KD, Bracke M, Heyerick A, van Breemen RB and Depypere H. Disposition of hop prenylflavonoids in human breast tissue. Mol Nutr Food Res 2010; 54: S284-294.